Meningococcal B

Phase 3Biologic

GSK

Meningococcal B is one of 58 biologic programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseNot yet recruiting

Rheumatic DiseasePhase 3

Not yet recruiting

Competition

Competitive Landscape

63 competitors in Rheumatic Disease

#DrugCompanyPhaseTrials

Voltaren

Aleve

Advil

Decadron

AAspen Global Incorporated

Approved

—5

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—6

Celebrex

PPhiladelphia Eye Associates

Approved

—7

Oruvail

WWyeth-Lederle Vaccines

Zovirax

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—10

Ansaid

PPharmacia and Upjohn

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Rheumatic Disease

NCT07252804

Clinical

Trials by Indication[1]

Satisfaction1 trial

Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction

Completed·CCanadian Immunization Research Network·Phase 4·NCT02868970·2,404 enrolled

Adolescent1 trial

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Completed· GSK logo

GSK·Phase 2·NCT00356369·500 enrolled

Rheumatic Disease1 trial

Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic Diseases

Not yet recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT07252804·263 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Meningococcal B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Meningococcal B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Meningococcal B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

Meningococcal B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Satisfaction1 trial

Adolescent1 trial

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News